Antibodies HK20 and D5 have been shown to target HIV-1 gp41, thereby inhibiting membrane fusion that facilitates viral entry. The binding picture is static, based on the X-ray crystal structures of the Fab regions and gp41 mimetic five-helix bundle. In this study, we carried out molecular dynamics simulation to provide the dynamic binding picture. Calculated binding free energies are within reasonable range of and follow the trend of the experimental values: −15.28 kcal/mol for HK20 Fab (expt. −11.60 kcal/mol) and −17.90 kcal/mol for D5 Fab (expt. −11.70 kcal/mol). Alanine scanning at protein–protein interface reveals that the highest contributors to binding for HK20 Fab are F54 and I56, both of VH region, as well as R30′ of VL region; wher...
The human monoclonal antibody (mAb) HK20 neutralizes a broad spectrum of primary HIV-1 isolates by t...
AbstractHelix–helix interactions in the putative three-helix bundle formation of the gp41 transmembr...
Despite the enormous efforts made to develop other fusion inhibitors for HIV, the enfuvirtide (known...
Multiple approaches are being utilized to develop therapeutics to treat HIV infection. One approach ...
The glycoproteins on the surface of human immunodeficiency virus (HIV) undergoes cascade of conforma...
Virus-cell fusion is the primary means by which the human immunodeficiency virus-1 (HIV) delivers it...
The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome ...
HIV-1 gp41 facilitates the viral fusion through a conformational switch involving the association of...
Drug resistance of mutations in HIV-1 protease (PR) is the most severe challenge to the long-term ef...
Background and the purpose of the study: The interactions between HIV-1 gp120 and mutated CD4 protei...
T-2410 and T-2429 are HIV fusion inhibitor peptides (FI) designed to present a higher efficiency eve...
The deep hydrophobic pocket of HIV-1 gp41 has been considered a drug target, but short-peptides targ...
International audienceThe HIV-1 gp120/gp41 trimer undergoes a series of conformational changes in or...
HIV-1 entry requires fusion of viral and cellular membranes, a process mediated by structural change...
The human monoclonal antibody (mAb) HK20 neutralizes a broad spectrum of primary HIV-1 isolates by t...
The human monoclonal antibody (mAb) HK20 neutralizes a broad spectrum of primary HIV-1 isolates by t...
AbstractHelix–helix interactions in the putative three-helix bundle formation of the gp41 transmembr...
Despite the enormous efforts made to develop other fusion inhibitors for HIV, the enfuvirtide (known...
Multiple approaches are being utilized to develop therapeutics to treat HIV infection. One approach ...
The glycoproteins on the surface of human immunodeficiency virus (HIV) undergoes cascade of conforma...
Virus-cell fusion is the primary means by which the human immunodeficiency virus-1 (HIV) delivers it...
The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome ...
HIV-1 gp41 facilitates the viral fusion through a conformational switch involving the association of...
Drug resistance of mutations in HIV-1 protease (PR) is the most severe challenge to the long-term ef...
Background and the purpose of the study: The interactions between HIV-1 gp120 and mutated CD4 protei...
T-2410 and T-2429 are HIV fusion inhibitor peptides (FI) designed to present a higher efficiency eve...
The deep hydrophobic pocket of HIV-1 gp41 has been considered a drug target, but short-peptides targ...
International audienceThe HIV-1 gp120/gp41 trimer undergoes a series of conformational changes in or...
HIV-1 entry requires fusion of viral and cellular membranes, a process mediated by structural change...
The human monoclonal antibody (mAb) HK20 neutralizes a broad spectrum of primary HIV-1 isolates by t...
The human monoclonal antibody (mAb) HK20 neutralizes a broad spectrum of primary HIV-1 isolates by t...
AbstractHelix–helix interactions in the putative three-helix bundle formation of the gp41 transmembr...
Despite the enormous efforts made to develop other fusion inhibitors for HIV, the enfuvirtide (known...